 | |  | |  | |  | |  | |  | |  | |  |
| IJCEP Copyright © 2007-All rights reserved. |
| International Journal of Clinical and Experimental Pathology |
Int J Clin Exp Pathol 1(2):147-156;2008
Original Article
Adenosquamous Carcinoma of Extrahepatic Bile Duct: Clinicopathologic Study of 12
Cases
Seung-Mo Hong, Mi-Jung Kim, Kee-Taek Jang, Ghil-Suk Yoon, HyungJun Cho, Henry F. Frierson Jr. and Eunsil Yu
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Kyungpook National
University Hospital, Daegu, Korea, Department of Statistics and Biostatistics, Korea University, Seoul, Korea, and Department of
Pathology, University of Virginia Health System, Charlottesville, VA.
Received 2 Aug 2007; accepted and available online 1 January 2008
Abstract: Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is
available on its clinicopathologic characteristics. Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their
clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas. The adenocarcinoma
component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was
slightly more frequent at the advanced edge (7 of 12 cases, 58%). Immunohistochemistry, available in 10 cases, revealed that S100A2
was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in
only 2 of 10 cases (20%, chi-square test, p=0.001). S100A4 expression did not show any difference between the two components.
Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median
survival, 32 months; log-rank test, p=0.003). Patients with predominant squamous cell carcinoma component at the leading edge had
worse survival than those without it. In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those
with pure adenocarcinoma. S100A2 immunohistochemical staining may be helpful in detecting the squamous component.
(IJCEP708005).
Key Words: Adenosquamous carcinoma, extrahepatic bile duct, cholangiocarcinoma, S100A2, prognosis
Full Text PDF
Address all correspondences to: Seung-Mo Hong, MD, PhD, Department of Pathology, Johns Hopkins Medical Institutions, 1550
Orleans Street, CRB 2, Suite 3M41, Baltimore, MD, 21209; Tel: 410-955-3511; Fax: 410-614-0671; E-mail: shong28@jhmi.edu
Original Article
Adenosquamous Carcinoma of Extrahepatic Bile Duct: Clinicopathologic Study of 12
Cases
Seung-Mo Hong, Mi-Jung Kim, Kee-Taek Jang, Ghil-Suk Yoon, HyungJun Cho, Henry F. Frierson Jr. and Eunsil Yu
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Kyungpook National
University Hospital, Daegu, Korea, Department of Statistics and Biostatistics, Korea University, Seoul, Korea, and Department of
Pathology, University of Virginia Health System, Charlottesville, VA.
Received 2 Aug 2007; accepted and available online 1 January 2008
Abstract: Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is
available on its clinicopathologic characteristics. Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their
clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas. The adenocarcinoma
component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was
slightly more frequent at the advanced edge (7 of 12 cases, 58%). Immunohistochemistry, available in 10 cases, revealed that S100A2
was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in
only 2 of 10 cases (20%, chi-square test, p=0.001). S100A4 expression did not show any difference between the two components.
Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median
survival, 32 months; log-rank test, p=0.003). Patients with predominant squamous cell carcinoma component at the leading edge had
worse survival than those without it. In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those
with pure adenocarcinoma. S100A2 immunohistochemical staining may be helpful in detecting the squamous component.
(IJCEP708005).
Key Words: Adenosquamous carcinoma, extrahepatic bile duct, cholangiocarcinoma, S100A2, prognosis
Full Text PDF
Address all correspondences to: Seung-Mo Hong, MD, PhD, Department of Pathology, Johns Hopkins Medical Institutions, 1550
Orleans Street, CRB 2, Suite 3M41, Baltimore, MD, 21209; Tel: 410-955-3511; Fax: 410-614-0671; E-mail: shong28@jhmi.edu